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Abstract  
Background: No data exists on inter-institutional differences in terms of adherence to international 
guidelines regarding the discontinuation of antithrombotics and rates of severe bleeding in coronary artery 
bypass grafting (CABG).  
Methods and Results: This is an analysis of 7118 patients from the prospective multicenter E-CABG registry 
who underwent isolated CABG in 15 European centers. Preoperative pause of P2Y12 receptor antagonists 
shorter than that suggested by the 2017 ESC guidelines (overall, 11.6%) ranged from 0.7% to 24.8% between 
centers (adjusted p<0.0001) and increased the rate of severe-massive bleeding (E-CABG bleeding grades 2-
3, OR 1.66, 95%CI 1.27-2.17; UDPB bleeding grades 3-4, OR 1.50, 95%CI 1.16-1.93). The incidence of 
resternotomy for bleeding (overall, 2.6%) ranged from 0% to 6.9% (adjusted p<0.0001) and surgical site 
bleeding (overall, 59.6%) ranged from 0% to 84.6% (adjusted p=0.003). The rate of the UDPB bleeding grades 
3-4 (overall, 8.4%) ranged from 3.7% to 22.3% (p<0.0001) and of the E-CABG bleeding grades 2-3 (overall, 
6.5%) ranged from 0.4% to 16.4% between centers (p<0.0001). Resternotomy for bleeding (adjusted OR 5.04, 
95%CI 2.85-8.92), UDPB bleeding grades 3-4 (adjusted OR 6.61, 95%CI 4.42-9.88) and E-CABG bleeding grades 
2-3 (adjusted OR 8.71, 95%CI 5.76-13.15) were associated with an increased risk of hospital/30-day mortality.  
Conclusions: Adherence to the current guidelines on the early discontinuation of P2Y12 receptor antagonists 
is of utmost importance to reduce excessive bleeding and early mortality after CABG. Inter-institutional 
variation should be considered for a correct interpretation of the results in multicentre studies evaluating 
perioperative bleeding and use of blood products. 
 
Key words: Bleeding; P2Y12; Antithrombotic; Coronary artery bypass grafting; Cardiac Surgery; Blood 
transfusion. 
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Introduction 
Patients undergoing isolated coronary artery bypass grafting (CABG) are often at risk of severe bleeding 
because of recent exposure to potent antithrombotics (1). Excessive bleeding and exposure to blood products 
are known to vary significantly between institutions, likely because of different patient-blood management 
strategies (2-5). However, there is no data on the possible impact of the individual patient risk of bleeding, 
late discontinuation of potent antiplatelets and differences in the rate and nature of excessive bleeding 
requiring reoperation as the main determinants of such inter-institutional differences. We sought to 
investigate any inter-institutional variation in the adherence to early discontinuation of antithrombotics, 
perioperative bleeding and use of blood products from the prospective, multicenter European Coronary 
Artery Bypass Grafting (E-CABG) registry. 
 
Methods 
The E-CABG registry is a prospective, multicenter observational study that enrolled patients undergoing 
isolated CABG at 16 European centers of cardiac surgery from Finland, France, Italy, Germany, Sweden and 
United Kingdom. The detailed protocol and definition criteria have been published earlier (6). Out of 7352 
patients enrolled in the E-CABG registry, 181 were operated after the recruitment period. Further 53 patients 
were excluded because they were recruited from one center only at the end of the study period. Overall, 
7118 patients operated in 15 centers from January 2015 to December 2016 had complete data on the 
covariates and outcomes of interest and were included in the present analysis. Data were collected 
prospectively and underwent robust validation and checking of its quality. Only data on timing of 
resternotomy and sources of bleeding were retrieved retrospectively. The study was approved by the 
Regional or Institutional Review Board of the participating centers. Informed consent was obtained when 
required by the Review Board, otherwise it was waived. The study is registered with the Clinical Trials 
Identifier NCT02319083 and was not supported financially. The participating centers did not adopt a common 
strategy of patient-blood management and the indication for blood transfusion varied between centers. 
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Point-of-care testing of coagulation was performed in all centers only in case of excessive intra- or 
postoperative bleeding.   
The risk of postoperative bleeding was estimated by the WILL-BLEED (8), CRUSADE (9), Papworth (10), TRUST 
(11), TRACK (12) and CathPCI bleeding risk scores (13). 
 
Outcomes 
The main outcome measures were reoperation for bleeding, severe-massive bleeding defined as the 
Universal Definition of Perioperative Bleeding (UDPB) classes 3-4 (7) and E-CABG bleeding classes 2-3 (6). 
Secondary outcomes were chest drain output at 12 hours after surgery, nadir hematocrit, red blood cell (RBC) 
transfusions, plasma transfusion, platelets transfusion, use of procoagulants, hospital/30-day death, length 
of stay in the intensive care unit, stroke, prolonged inotropic support, deep sternal wound 
infection/mediastinitis, acute kidney injury, renal replacement therapy, and postoperative atrial fibrillation.  
Reoperation for bleeding was defined as any resternotomy for excessive bleeding performed during the index 
hospitalization. According to the E-CABG bleeding classification, severe-massive bleeding was defined as any 
reoperation for excessive bleeding and/or transfusion >4 units of red blood cells (6). According to the UDPB 
bleeding classification, severe-massive bleeding was defined as chest tube blood loss within 12 hours >1000 
mL and/or reoperation for excessive bleeding and/or transfusion >4 units of red blood cells and/or 
transfusion >4 units of fresh frozen plasma after closure of the chest (7). Use of procoagulants was defined 
as any administration of fibrinogen, prothrombin complex concentrate, cryoprecipitate and recombinant 
factor VIIa intraoperatively during the index hospitalization. Nadir levels of hematocrit were defined as the 
lowest value measured on the day of surgery. Hospital/30-day mortality was defined as all-cause death 
occurring during the index hospitalization or within 30 days after CABG. Intensive care unit length of stay was 
defined as the number of days of treatment in the intensive care unit considering also any readmission during 
the same index hospitalization. Stroke was defined as any focal or global neurological syndrome occurring 
during the index hospitalization not resolving within 24 h. The diagnosis and nature of stroke was based on 
findings at computed tomography and/or magnetic resonance imaging of the brain and confirmed by a 
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neurologist. Need of intra-aortic balloon pump and/or extra-corporeal membrane oxygenation refers to the 
use of these mechanical circulatory supports method any time after surgery and during the index 
hospitalization. Deep sternal wound and mediastinitis were defined as a surgical site infection occurring 
within 3 months after surgery involving deep soft tissues, sternum and/or mediastinum with purulent 
drainage or abscess, with or without fever (>38°C), detected at direct examination, during reoperation, or 
radiologic examination and requiring antibiotic treatment with or without reoperation. Postoperative atrial 
fibrillation was defined as any new event of atrial fibrillation occurred after CABG and detected at 
electrocardiogram, requiring or not pharmacological/electrical cardioversion. Acute kidney injury was 
defined as an increase in serum creatinine ≥1.5 times the baseline level or serum creatinine increase ≥26.5 
μmol/l within seven days after surgery and/or de novo renal replacement therapy. Patients with baseline 
estimated glomerular filtration rate <15 mL/min/1.73 m2 or on chronic dialysis were excluded from the 
analysis on postoperative acute kidney injury.  
 
Statistical Analysis  
Statistical analysis was performed using SPSS statistical software v. 24.0 (IBM Corporation, New York, USA), 
and Stata v. 14.2 (StataCorp LLC, Texas, USA). Covariates and outcomes were reported as counts and 
percentages, and as mean and standard deviation. The Mann-Whitney, Kruskall-Wallis, Chi-square, Fisher 
Exact tests were used to compare baseline and operative covariates between the study cohorts. Predictive 
ability of bleeding risk scores were evaluated by the area under the receiver operating (ROC) curves and these 
were compared by the de Long’s test. Since the study cohorts had a significantly different distribution of 
baseline and operative covariates, logistic regression models evaluating the primary outcomes were adjusted 
using the enter method for the following covariates: age, gender, baseline hemoglobin, baseline platelets 
count <150 109/L, estimated glomerular filtration rate, P2Y12 receptor inhibitors pause shorter than that 
suggested by the 2017 European Society for Cardiology (ESC) guidelines, aspirin administered within 7 days 
from surgery, oral anticoagulants administered within 2 days from surgery, diabetes, stroke or transient 
ischemic attack, atrial fibrillation, pulmonary disease, extracardiac arteriopathy, emergency procedure, left 
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ventricular ejection fraction ≤50%, critical preoperative state, prior cardiac surgery, prior percutaneous 
coronary intervention, off-pump surgery, bilateral internal mammary artery grafting and number of distal 
anastomoses. Continuous variables were left untransformed. We did not include the duration of cross-
clamping and cardiopulmonary bypass in to regression models because a significant number of patients in 
this series underwent off-pump CABG. The goodness of fit of regression models were tested with the Hosmer-
Lemeshow’s test. The anonymized center codes were ranked in descending order of center volume and was 
included in the regression models as a factor covariate. The risk-adjusted rate of adverse binary events was 
calculated by dividing, for each participating center, the observed number of events by the expected number 
of events, and by multiplying this ratio by the average event rate of the entire series. The expected numbers 
of events were estimated using logistic regression.  The estimated risk-adjusted rates of adverse events with 
95% confidence intervals (CI) were summarized in caterpillar plots with the x-axis ordered for increasing 
adjusted rates. All tests were two-sided with the alpha level set at 0.05 for statistical significance. 
 
Results 
Baseline risk factors 
Their baseline characteristics, operative data, preoperative antithrombotic regimen as well as bleeding risk 
are summarized in Tables 1 and 2. 
Univariate analysis showed that participating centers differed in all baseline risk factors. In particular, the 
prevalence of recent myocardial infarction ranged from 17.9% to 62.5%, left ventricular ejection fraction 
≤50% from 16.9% to 48.7% and critical preoperative state from 1.5% to 21.8% (Tab. 1). Such imbalances in 
baseline risk factors translated in marked inter-institutional differences in the operative risk as shown by the 
mean EuroSCORE II, which ranged from 1.6±1.3% to 5.2±6.8% (p<0.0001, Tab. 1). Similarly, also the surgical 
approach differed markedly between centers as the proportion of bilateral internal mammary artery grafting 
ranged from 0.9% to 88.5% and of off-pump surgery from 0.9% to 57.6% (Tab. 1). 
 
Preoperative antithrombotic regimen  
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Aspirin were discontinued less than seven days before CABG in 88.4% of patients (range between centers, 
67.3-98.6%, p<0.0001) (Tab. 2). When adjusted for multiple covariates and participating centers, aspirin 
discontinued less than seven days was not associated with an increased risk of resternotomy for bleeding 
(p=0.898) as well as severe-massive bleeding defined as E-CABG bleeding grades 2-3 (p=0.251) and UDPB 
bleeding grades 3-4 (p=0.997). 
Low molecular weight heparin, unfractionated heparin and fondaparinux were administered preoperatively 
in 41.8% of patients (range between centers, 4.4-97.4%, p<0.0001) (Tab. 2). When adjusted for multiple 
covariates and participating centers, preoperative exposure to low molecular weight heparin, unfractionated 
heparin and fondaparinux showed was not associated with an increased risk of resternotomy for bleeding 
(p=0.264). However, these drugs increased significantly the risk of severe-massive bleeding defined as E-
CABG bleeding grades 2-3 (p=0.001, OR 1.51, 95%CI 1.17-1.95) and UDPB bleeding grades 3-4 (p=0.016, OR 
1.34, 95%CI 1.05-1.69).  
Overall, 14.6% of patients were operated on with a pause of P2Y12 receptor antagonists of <5 days from 
surgery (range between centers, 0.7-25.0%, p<0.0001) (Fig. 1). Similarly, 11.6% of patients were operated on 
with a pause of P2Y12 receptor antagonists shorter than recently suggested by the 2017 ESC guidelines, i.e. 
ticagrelor <3 days, clopidogrel <5 days and prasugrel <7 days before CABG (range between centers, 0.7-
24.8%, p<0.0001) (Fig. 1).   
When adjusted for recent myocardial infarction, left ventricular ejection fraction ≤50%, critical preoperative 
state and emergency operation, the proportion of patients with pause of P2Y12 receptor antagonists <5 days 
from surgery (p<0.0001) and pause of P2Y12 receptor antagonists shorter than recently suggested by the 
2017 ESC guidelines (p<0.0001) significantly differed between centers. 
Logistic regression adjusted for multiple covariates and participating centers showed that patients operated 
on with a pause of P2Y12 receptor antagonists shorter than those recently suggested by the 2017 ESC 
guidelines had a significantly increased risk of E-CABG bleeding grades 2-3 (OR 1.66, 95%CI 1.27-2.17) and 
UDPB bleeding grades 3-4 (OR 1.50, 95%CI 1.16-1.93), but not of resternotomy for bleeding (adjusted OR 
1.22, 95%CI 0.80-1.87). Similarly, logistic regression adjusted for multiple covariates and participating 
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centers showed that patients operated on with a pause of P2Y12 receptor antagonists <5 days had a 
significantly increased risk of E-CABG bleeding grades 2-3 (OR 1.78, 95%CI 1.38-2.29) and UDPB bleeding 
grades 3-4 (OR 1.43, 95%CI 1.12-1.83), whilst a trend toward increased risk of resternotomy for bleeding 
was observed as well (adjusted OR 1.36, 95%CI 0.92-2.01). 
 
Estimated bleeding risk 
The bleeding risk estimated by the WILL-BLEED, CRUSADE, Papworth, TRUST, TRACK and CathPCI risk scores 
were significantly different between centers (all scores, p<0.0001, Tab. 2). Among these bleeding risk scoring 
methods, the WILL-BLEED and the CathPCI bleeding scores had the largest area under the curve to predict 
resternotomy for bleeding, E-CABG bleeding grades 2-3 and UDPB bleeding grades 3-4 (Tab. 3). Similar results 
were observed among patients with and without preoperative pause of P2Y12 receptor antagonists 
according to the 2017 ESC guidelines (Tab. 3). The WILL-BLEED score had a significantly larger area under the 
curve to predict E-CABG bleeding grades 2-3 (p=0.024) than the CathPCI bleeding score, but not for 
resternotomy for bleeding (p=0.456) and UDPB bleeding grades 3-4 (p=0.483). The mean WILL-BLEED score 
ranged from 2.3±3.0 to 5.6±4.6 and the mean CathPCI score ranged from 36±17 to 52±20 between 
participating centers (Tab. 2). 
 
Resternotomy for bleeding 
Overall, 186 patients (2.6%) underwent resternotomy for excessive bleeding with significant variation 
between centers (p<0.0001, Tab. 4). One-hundred and forty five patients (75.7%) underwent resternotomy 
for bleeding within 12 hours from surgery and their mean chest drainage output was 845±376 mL (median, 
800 mL, IQR 400, range 200-2000 mL). Among these patients, the amount of blood loss until reoperation 
significantly differed between centers (range, mean 607±257 mL to 1073±505 mL, p<0.0001). A significant 
difference between centers was observed also in terms of incidence of late resternotomies (later than 12 
hours after surgery: range, 0-87.5%, p<0.0001, Tab. 4).  
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Surgical site bleeding was identified in 89 patients (48.6%), diffuse bleeding in 74 patients (40.4%), whilst 
both diffuse and surgical site bleeding was identified in 20 patients (10.8%). No specific data on the site of 
bleeding was reported in three patients. Surgical site bleeding was detected in 59.6% of these patients with 
significant variation between centers (range, 0% to 84.6%, adjusted p=0.003, Tab. 4, Fig. 2). Details on the 
sources of bleeding are reported in Table 5. Two or more sources of surgical bleeding were observed in 12 
patients. Patients with diffuse bleeding had a higher risk of hospital/30-day mortality compared to patients 
with any surgical site bleeding (13.5% vs. 9.1%, adjusted OR 3.195, 95%CI 0.870-11.730), but the difference 
did not reach statistical significance. 
 
Red blood cell transfusion 
The rate of RBC transfusion in the overall series was 40.9% and ranged from 24.1% to 71.3% between centers 
(p<0.0001, Tab. 4). Caterpillar plot showed that three centers (F, K, I) had a significantly higher adjusted rates 
and four centers (B,C,D,M) had significantly lower adjusted rates of RBC transfusion. 
 
Severe-massive perioperative bleeding 
The rate of UDPB bleeding grades 3-4 in the overall series was 8.4% and ranged from 3.7% to 22.3% between 
centers (p<0.0001, Tab. 4). The rate of E-CABG bleeding grades 2-3 in the overall series was 6.5% and ranged 
from 0.4% to 16.4% between centers (p<0.0001, Tab. 4). Caterpillar plot showed that a number of centers 
had a significantly lower and higher risk of severe-massive bleeding, respectively (Fig. 3). However, centers 
performed differently in terms of UDPB and E-CABG severe-massive bleeding. When UDPB bleeding grades 
3-4 were chosen as an endpoint for its more comprehensive bleeding- and blood products-related 
parameters, three centers (C,K,I) had significantly higher risk-adjusted rates of severe-massive bleeding, 
while six centers (B,E,H,J,M,N) had a significantly lower risk-adjusted rates of severe-massive bleeding (Fig. 
3). Three centers (C,F,I) had significantly higher and three centers (G,K,M) significantly lower risk-adjusted 
rates of E-CABG bleeding grades 2-3 (Fig. 3). 
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Clinical implications of severe perioperative bleeding 
When adjusted by multiple covariates, resternotomy for bleeding (adjusted OR 5.042, 95%CI 2.85-8.92), 
UDPB bleeding grades 3-4 (adjusted OR 6.61, 95%CI 4.42-9.88) and E-CABG bleeding grades 2-3 (adjusted OR 
8.71, 95%CI 5.76-13.15) were associated with an increased risk of hospital/30-day mortality.  
Reoperation for bleeding and severe-massive bleeding were predictive of hospital/30-day mortality also in 
patients undergoing elective CABG without prior myocardial infarction and with preserved left ventricular 
function (2621 patients included in the analysis, resternotomy for bleeding: adjusted OR 11.57, 95%CI 2.91-
45.95, UDPB bleeding grades 3-4, OR 15.90, 95%CI 5.83-43.36; E-CABG bleeding grades 2-3, adjusted OR 
21.87, 95%CI 7.96-60.06).  
 
Discussion 
This study showed that: 1) the risk of postoperative bleeding as assessed by several risk scores significantly 
varied between centers; 2) adherence to the currently recommended discontinuation period for P2Y12 
receptor antagonists varied significantly between centers and this had a significant impact on the occurrence 
of postoperative major bleeding; 3) the rate of resternotomy for excessive bleeding was different between 
centers and was independent of any recent exposure to P2Y12 receptor antagonists or individual bleeding 
risk; 4) surgical site bleeding significantly varied between centers and was observed in two thirds of patients 
undergoing resternotomy; 5) the rate of severe-massive bleeding differed significantly between centers; 6) 
resternotomy for bleeding and severe-massive bleeding according to the UDPB and E-CABG definition criteria 
were associated with an excessive risk of early mortality.   
Goodnough et al. (14) in 1991 provided evidence of a significant inter-institutional variability of the use of 
blood products after CABG. The present analysis along with a few previous studies (2-5) confirm that such 
inter-institutional differences persisted during the last three decades most likely because of a lack of 
common, effective patient-blood management strategy. The uncertainty about the safety of a liberal 
threshold for hemoglobin level in RBC transfusion is one of the key factors underlying these differences. A 
recent study by Murphy et al. (15) failed to demonstrate the superiority of a restrictive over a liberal policy 
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of blood transfusion in patients undergoing adult cardiac surgery. This means that strategies aiming to 
improve the outcomes by preventing perioperative blood loss may be more efficacious than targeting only a 
reduction of the exposure to allogenic blood. Indeed, the present findings demonstrate a large heterogeneity 
in the estimated risk of bleeding, prevalence of early discontinuation of potent antiplatelets and rates of 
severe-massive bleeding, which had a significant impact on the outcome of patients undergoing isolated 
CABG. In this regard, our decision to investigate severe bleeding rather than the exposure to any amount of 
RBC transfusion as in previous studies (2-5) was substantiated by the evidence of a formidable risk of early 
mortality in patients undergoing reoperation for bleeding (16) and/or transfusion of more than four units of 
RBCs (7,17).  
This study showed that the measures to counteract increased bleeding risk, of early discontinuation of potent 
antiplatelets and to reduce of the risk of surgical bleeding should be implemented in centers with high rates 
of severe bleeding. The combined evidence of an individual surgeon’s impact on perioperative blood loss (18) 
and a high rate of surgical sources of bleeding detected at reoperation (19) suggests that meticulous surgical 
technique could be an important issue in preventing significant bleeding. In fact, the individual patient’s risk 
of bleeding and recent exposure to potent antiplatelets were not associated with an increased risk of 
reoperation for bleeding. This finding further confirm that excessive bleeding requiring reoperation is most 
often due to factors related to surgical technique rather than perioperative coagulopathy. Furthermore, 
these findings may explain why the discrimination ability of current bleeding risk scores in predicting severe-
massive bleeding is limited (Tab. 3). 
One of the main findings of this analysis is the significant heterogeneity of preoperative exposure to P2Y12 
receptor antagonists, which ranged from 7% to 63% in the participating centers (Tab. 2). Even more striking 
is the inter-institutional difference in the incidence of preoperative discontinuation of P2Y12 receptor 
antagonists <5 days from surgery or with a pause a suggested by the 2017 ESC guidelines, i.e. ticagrelor <3 
days, clopidogrel <5 days and prasugrel <7 days before CABG (range between centers, 0.7-24.8%, p<0.0001) 
(Fig. 1). The attention to the currently recommended washout period for P2Y12 receptor antagonists to 
minimize postoperative bleeding markedly varied between institutions and, when these guidelines were not 
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followed, this resulted in an increased risk of severe-massive defined according to the E-CABG and UDPB 
criteria. When UDPB bleeding grades 3-4 were chosen as an endpoint for its more comprehensive 
parameters, i.e. chest drainage output, resternotomy for bleeding, transfusion of >4units of RBC and/ fresh 
frozen plasm and use of procoagulants, three centers had significantly higher and six centers significantly 
lower rates of severe-massive bleeding compared to the results of overall series also when adjusted for 
multiple baseline risk factors (Fig. 3). These findings confirm that a few centers adopted effective strategies 
to prevent significant blood loss after CABG and this effect was evident when adjusted for potential 
confounders.  
A few limitations may affect the results of this study. First, we do not have preoperative data on platelet 
reactivity, fibrinogen level, thrombin generation and other coagulation parameters for a detailed inter-
institutional analysis of baseline coagulopathies in these patients. Second, the lack of specific data on point-
of-care testing of postoperative coagulopathy prevents a more in depth analysis of the causes of excessive 
postoperative bleeding. Third, we do not have data on individual surgeons, which prevents conclusive results 
on the impact of individual surgical skills on postoperative bleeding end-points. Fourth, stratification of the 
severity of perioperative bleeding in cardiac surgery has been based mainly on the evaluation of RBC 
transfusion, but this fails to identify those patients with significant bleeding and high risk of other adverse 
events. The UDPB and E-CABG bleeding classifications are more detailed and specific tools for stratification 
of the severity of perioperative bleeding and its prognostic implications (20), but they differ significantly in 
their characteristics. Therefore, participating centers to this study behaved somewhat differently in terms of 
rates of severe-massive bleeding as defined by the UDPB and E-CABG bleeding classifications. Such 
heterogeneity makes these findings generalizable. 
 
Conclusions 
This study documented a significant inter-institutional heterogeneity in the estimated risk of bleeding, 
preoperative antithrombotic policy and discontinuation of antiplatelet drugs, incidence of severe-massive 
bleeding as well as in the use of blood products. The present findings suggest that inter-institutional variation 
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of perioperative bleeding and use of blood products should be considered for a correct interpretation of the 
results of multicentre studies. Adherence to the current guidelines on the early discontinuation of P2Y12 
receptor antagonists and meticulous surgical technique aimed to reduce surgical site bleeding seems to be 
of utmost importance to prevent excessive bleeding, exposure to blood products and improve the outcome 
after CABG.  
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Table 1. Baseline characteristics and operative data of patients undergoing coronary surgery in the participating centers. 
 Participating centers 
Covariates Overall A 
 
 
B C D E F G H I J K L M N O p-value 
 no. 7118 no. 1045 no. 763 no. 659 no. 613 no. 523 no. 503 no. 494 no. 444 no. 433 no. 415 no. 404 no. 226 no. 224 no. 205 no. 167  
Baseline risk factors                  
Age (years) 67.4±9.4 67.8±9.6 67.6±9.2 66.6±9.0 66.1±8.9 69.3±9.8 67.9±9.5 64.8±9.0 68.1±9.6 68.3±8.5 66.1±9.1 68.1±9.7 66.1±9.0 67.4±9.3 67.9±10.2 68.3±8.7 <0.0001 
Female 1160 (16) 153 (15) 126 (17) 79 (12) 93 (15) 102 (20) 88 (18) 90 (18) 80 (18) 90 (21) 67 (16) 55 (14) 42 (19) 37 (17) 32 (16) 26 (16) 0.014 
Body mass index 27.5±4.2 27.9±4.4 28.0±4.4 26.7±3.6 27.7±4.3 27.3±4.5 27.2±4.1 27.4±3.9 27.4±4.0 28.1±4.4 27.7±4.0 27.4±4.2 27.6±4.1 26.6±3.5 26.8±3.5 26.8±3.7 <0.0001 
eGFR (mL/min/1.73 m2) 76±20 73±20 80±19 78±17 77±19 73±21 72±21 85±22 73±23 78±20 76±20 76±20 77±20 76±22 72±20 75±20 <0.0001 
Anemia 1615 (23) 179 (17) 168 (22) 70 (11) 136 (22) 93 (18) 156 (31) 138 (28) 129 (29) 117 (27) 90 (22) 139 (34) 54 (24) 51 (23) 67 (33) 28 (17) <0.0001 
Platelets count <150 109/L 588 (8) 54 (5) 83 (11) 52 (8) 39 (7) 26 85) 51 (10) 50 (10) 42 (10) 39 (9) 32 (8) 62 (15) 15 (7) 10 (5) 20 (10) 13 (8) <0.0001 
Dialysis 78 (1) 14 (1) 3 (0) 3 (0) 4 (1) 4 (1) 6 (1) 7 (1) 17 (4) 4 (1) 4 (1) 3 81) 1 (0) 4 (2) 4 (2) 0 <0.0001 
Diabetes 2215 (31) 269 (26) 235 (31) 123 (19) 184 (30) 196 (38) 160 (32) 187 (38) 143 (32) 142 (33) 195 (47) 58 (14) 107 (47) 82 (37) 74 (36) 60 (36) <0.0001 
Recent MI 2291 (32) 247 (24) 158 (21) 172 (26) 149 (24) 143 (27) 145 (29) 222 (45) 201 (45) 230 (53) 171 (41) 98 (24) 95 (42) 140 (63) 90 (44) 30 (18) <0.0001 
Prior stroke/TIA 430 (6) 93 (9) 32 (4) 30 (5) 48 (8) 16 (3) 35 (7) 25 (5) 11 (3) 41 (10) 27 (7) 9 (2) 16 (2) 16 (7) 11 (5) 20 (12) <0.0001 
Atrial fibrillation 566 (8) 116 (11) 54 (7) 31 (5) 43 (7) 57 (11) 50 (10) 23 (5) 33 (7) 47 (11) 25 (6) 29 (7) 16 (7) 11 (5) 16 (8) 15 (9) <0.0001 
Pulmonary disease 738 (10) 138 (13) 58 (8) 41 (6) 41 (7) 39 (8) 26 (5) 120 (24) 11 (3) 54 (13) 25 (6) 28 (7) 30 (13) 47 (21) 60 (29) 20 (12) <0.0001 
Extracardiac arteriopathy 1637 (23) 272 (26) 117 (15) 118 (18) 52 (9) 163 (31) 153 (30) 142 (29) 101 (23) 44 (10) 101 (25) 84 (21) 73 (32) 75 (34) 72 (35) 70 (42) <0.0001 
LVEF ≤50% 2059 (29) 339 (32) 140 (18) 102 (16) 237 (39) 132 (25) 131 (26) 194 (39) 154 (35) 112 (26) 202 (49) 86 (21) 68 (30) 38 (17) 82 (40) 42 (25) <0.0001 
Prior PCI 1490 (21) 253 (24) 126 (17) 161 (24) 115 (19) 130 (25) 89 (18) 109 (22) 70 (16) 91 (21) 91 (22) 44 (11) 72 (32) 52 (23) 43 (21) 44 (26) <0.0001 
Prior cardiac surgery 39 (1) 4 (0) 5 (1) 1 (0) 2 (0) 1 (0) 2 (0) 1 (0) 8 (2) 7 (2) 1 (0) 4 (1) 0 2 (1) 0 1 (1) <0.0001 
Critical preoperative state 450 (6) 35 (3) 52 (7) 18 (3) 9 (2) 14 (3) 70 (13) 12 (2) 12 (3) 44 (10) 36 (9) 88 (22) 14 (6) 7 (3) 26 (13) 13 (8) <0.0001 
Emergency procedure 334 (5) 106 (10) 24 (3) 9 (1) 5 (1) 59 (11) 19 (4) 19 (4) 11 (3) 43 (10) 2 (1) 11 (3) 12 (5) 1 (0) 10 (5) 3 (2) <0.0001 
EuroSCORE II (%) 2.8±4.1 2.8±4.3 2.1±3.0 1.6±1.3 1.9±2.4 3.0±4.6 3.4±3.8 2.3±3.0 3.1±4.1 4.1±6.3 2.6±3.2 4.1±5.8 3.7±5.1 2.5±3.5 5.2±6.8 2.8±4.7 <0.0001 
                  
Operative data                  
Off-pump surgery 1470 (21) 517 (50) 5 (1) 84 (13) 6 (1) 171 (33) 10 (2) 92 (19) 4 (1) 241 (56) 239 (58) 14 (4) 34 (15) 23 (10) 9 (4) 21 (13) <0.0001 
No. of  distal anastomoses 2.7±0.9 2.3±0.8 2.7±0.7 2.4±0.8 3.0±0.8 3.1±1.0 2.4±0.7 2.3±0.8 2.8±0.8 3.6±1.0 2.4±0.8 3.5±1.0 2.4±1.0 2.6±0.8 2.7±0.9 2.9±1.0 <0.0001 
BIMA grafting 2578 (36) 582 (56) 78 (10) 466 (71) 243 (40) 463 (89) 5 (1) 5 (1) 47 (11) 17 (4) 245 (59) 273 (68) 35 (16) 49 (22) 50 (24) 20 (12) <0.0001 
Continuous variables are reported as the mean ± standard deviation. Categorical variables are reported as counts and percentages. Percentages are rounded to nearest integer. Anemia is defined 
as <12.0g/L in women and <13.0 g/L in men. eGFR indicates estimated glomerular filtration rate according to the MDRD equation; MI, myocardial infarction; TIA, transient ischemic attack; PCI, 
percutaneous coronary intervention; LVEF, left ventricular ejection fraction; EuroSCORE, European System for Cardiac Operative Risk Evaluation; BIMA bilateral internal mammary artery. Clinical 
variables are according to the EuroSCORE II definition criteria. 
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Table 2. Preoperative antithrombotics and bleeding risk scores in patients undergoing coronary surgery. 
 Participating centers 
Covariates Overall A B C D E F G H I J K L M N O p-value 
 no. 7118 no. 1045 no. 763 no. 659 no. 613 no. 523 no. 503 no. 494 no. 444 no. 433 no. 415 no. 404 no. 226 no. 224 no. 205 no. 167  
Antithrombotics                  
Aspirin 6364 (89) 883 (85) 710 (93) 616 (94) 565 (92) 474 (91) 422 (84) 473 (96) 441 (99) 394 (91) 349 (84) 272 (67) 186 (82) 216 (97) 199 (97) 163 (98) <0.0001 
Aspirin pause<7 days 6285 (88) 881 (84) 705 (93) 613 (93) 565 (92) 475 (91) 407 (82) 463 (94) 438 (99) 392 (91) 329 (79) 272 (67) 173 (77) 210 (94) 199 (97) 163 (98) <0.0001 
P2Y12 receptor antagonists 2405 (34) 278 (27) 53 (7) 220 (33) 360 (59) 186 (36) 179 (36) 309 (63) 89 (49) 210 (49) 204 (49) 32 (8) 94 (42) 72 (32) 75 (37) 44 (26) <0.0001 
Ticagrelor 1038 (15) 95 (9) 22 (3) 76 (12) 278 (45) 85 (16) 43 (9) 123 (25) 30 (7) 78 (18) 75 (18) 10 (3) 49 (22) 24 (11) 38 (19) 12 (7) <0.0001 
Ticagrelor pause<3 days 212 (3) 90 (9) 3 (0) 4 (1) 23 (4) 27 (5) 7 (1) 6 (1) 3 (1) 27 (6) 6 (1) 0 2 (1) 2 (1) 9 (4) 2 (1) <0.0001 
Clopidogrel 1329 (19) 186 (18) 26 (3) 140 (21) 84 (14) 104 (20) 135 (27) 181 (37) 57 (13) 135 (31) 111 (27) 23 (6) 43 (19) 46 (21) 27 (13) 31 (19) <0.0001 
Clopidogrel pause<5 days 573 (8) 166 (16) 12 (2) 25 (4) 34 (6) 71 (14) 62 (12) 28 (6) 12 (3) 65 (15) 62 (15) 3 (1) 4 (2) 7 (3) 13 (6) 9 (5) <0.0001 
Prasugrel 66 (1) 2 (0) 5 (1) 8 (1) 1 (0) 0 4 (1) 7 (1) 3 (1) 1 (0) 19 (5) 0 2 (1) 2 (1) 11 (5) 1 (1) <0.0001 
Prasugrel pause<7 days 46 (1) 2 (0) 4 (1) 2 (0) 1 (0) 0 3 (1) 3 (1) 2 (1) 1 (0) 13 (3) 0 2 (1) 1 (0) 11 (5) 1 (1) <0.0001 
P2Y12 rec. antagonists pause<5 days 1041 (15) 258 (25) 26 (3) 37 (6) 134 (22) 127 (24) 81 (16) 47 (10) 31 (7) 113 (26) 92 (22) 3 (1) 11 (5) 20 (9) 45 (22) 16 (10) <0.0001 
P2Y12 rec. antagonists pause shorter 
than 2017 ESC guidelines*  
826 (12) 256 (25) 19 (3) 31 (5) 56 (9) 98 (19) 71 (14) 37 (8) 17 (4) 93 (22) 81 (20) 3 (1) 9 (4) 10 (5) 33 (16) 12 (7) <0.0001 
Oral anticoagulants  47 (5) 8 (1) 25 (4) 25 (4) 3 (1) 18 (4) 5 (1) 12 (3) 39 (9) 6 (1) 13 (3) 3 (1) 7 (3) 4 (2) 8 (5) <0.0001 
Warfarin/coumadin 162 (2) 28 (3) 5 (1) 14 (2) 14 (2) 3 (1) 17 (3) 4 (1) 11 (3) 33 (8) 2 (1) 12 (3) 3 (1) 6 (3) 3 (2) 7 (4) <0.0001 
Rivaroxaban 32 (0) 14 (1) 1 (0) 7 (1) 3 (1) 0 0 0 0 4 (1) 2 (1) 0 0 1 (0) 0 0 <0.0001 
Dabigatran 15 (0) 2 (0) 0 2 (0) 4 (1) 0 1 (0) 0 0 3 (1) 1 (0) 1 (0) 0 0 0 1 (1) 0.203 
Apixaban 20 (0) 3 (0) 2 (0) 2 (0) 4 (1) 0 0 1 (0) 1 (0) 1 (0) 1 (0) 0 0 0 1 (0) 0 0.712 
Oral anticoagulants within 2 days 52 (1) 10 (1) 0 0 5 (1) 1 (0) 6 (1) 1 (0) 0 26 (6) 0 1 (0) 0 2 (1) 0 0 <0.0001 
LMWH / Fondaparinux / Unfractionated 
heparin 
2974 (42) 939 (90) 115 (15) 32 (5) 278 (45) 49 (9) 320 (64) 481 (97) 101 (23) 224 (52) 125 (30) 36 (9) 123 (54) 22 (10) 106 (52) 23 (14) <0.0001 
LMWH 2187 (31) 652 (62) 1 (0) 24 (4) 14 (2) 6 (1) 286 (57) 480 (97) 100 (23) 223 (52) 125 (30) 36 (9) 93 (41) 22 (10) 104 (51) 21 (13) <0.0001 
Fondaparinux 352 (5) 4 (0) 0 8 (2) 266 (43) 43 (8) 28 (6) 0 0 0 0 0 0 0 1 (1) 2 (1) <0.0001 
Unfractionated heparin 476 (7) 311 (30) 114 (15) 0 0 0 15 (3) 1 (0) 1 (0) 1 (0) 0 0 32 (14) 0 1 (1) 0 <0.0001 
Thrombolysis 20 (0) 0 1 (0) 1 (0) 0 0 0 6 (1) 1 (0) 6 (1) 5 (1) 0 0 0 0 0 <0.0001 
Bivaluridin 5 (0) 0 0 0 1 (0) 0 0 0 0 4 (1) 0 0 0 0 0 0 <0.0001 
Tirofiban 80 (1) 1 (0) 13 (2) 1 (0) 2 (0) 0 2 (0) 20 (4) 13 (3) 1 (0) 0 0 1 (0) 6 (3) 16 (8) 4 (2) <0.0001 
Cangrelor 1 (0) 0 0 0 1 (0) 0 0 0 0 0 0 0 0 0 0 0 0.716 
Eptifibatide 19 (0) 0 0 0 0 0 0 0 0 13 (3) 1 (0) 0 1 (0) 0 0 0 <0.0001 
                  
Bleeding risk scores                  
WILL-BLEED score 4.0±3.6 3.7±3.2 2.7±3.2 2.3±3.0 3.7±3.2 3.4±3.6 5.2±3.8 5.5±3.2 4.3±3.5 5.6±4.6 4.2±3.7 4.2±3.7 4.2±3.7 4.6±3.0 5.9±3.6 3.0±3.7 <0.0001 
CRUSADE score 26±14 25±13 24±13 23±11 23±12 28±14 28±14 25±14 30±15 26±15 29±14 24±13 28±14 27±14 30±14 27±14 <0.0001 
Papworth score 1.0±1.2 0.9±0.8 0.8±1.2 0.8±0.8 1.0±0.8 1.0±0.9 1.4±1.4 1.0±0.8 1.4±1.4 1.2±1.5 0.6±0.7 1.5±1.9 1.2±1.8 0.6±0.6 1.4±0.8 0.8±2.1 <0.0001 
TRUST score 2.2±1.3 1.9±1.3 1.9±1.3 1.8±1.2 2.1±1.3 2.3±1.4 2.6±1.4 2.3±1.4 2.7±1.4 2.4±1.4 1.8±1.2 2.6±1.3 2.4±1.4 1.9±1.3 2.8±1.3 1.9±1.3 <0.0001 
TRACK score 6.7±5.1 6.3±4.7 6.8±5.1 5.8±4.2 5.7±4.5 7.3±5.1 6.8±5.3 6.4±5.2 8.6±6.0 7.6±5.5 5.8±4.8 7.5±5.2 6.5±5.1 7.0±4.8 7.2±4.9 6.4±4.4 <0.0001 
CathPCI score 43±21 42±22 38±19 36±17 43±18 47±24 51±20 46±22 52±20 49±22 36±17 50±20 45±23 35±17 52±20 36±19 <0.0001 
Continuous variables are reported as the mean ± standard deviation. Categorical variables are reported as counts and percentages. Percentages are rounded to nearest integer. *, Ticagrelor 
paused at least 3 days, clopidogrel at least 5 days and prasugrel at least 7 days before surgery according to the 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease (); 
LMWH: low molecular weight heparin. 
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Table 3. C-statistics of bleeding risk scoring methods in predicting resternotomy for bleeding, UDPB bleeding grades 3-4 and E-CABG bleeding 
grades 2-3. 
Bleeding risk scores Resternotomy for bleeding UDPB bleeding grades 3-4 E-CABG bleeding grades 2-3 
Overall series    
WILL-BLEED score 0.595 (0.551-0.640) 0.608 (0.584-0.633) 0.706 (0.679-0.732) 
CRUSADE score 0.541 (0.500-0.583) 0.555 (0.530-0.580) 0.657 (0.629-0.685) 
Papworth score 0.531 (0.489-0.573) 0.556 (0.532-0.580) 0.582 (0.556-0.608) 
TRUST score 0.535 (0.492-0.578) 0.571 (0.546-0.595) 0.654 (0.627-0.681) 
TRACK score 0.515 (0.471-0.558) 0.553 (0.527-0.578) 0.625 (0.596-0.655) 
CathPCI score 0.582 (0.539-0.625) 0.603 (0.579-0.627) 0.683 (0.656-0.710) 
    
P2Y12 rec. antagonists pause shorter 
than suggested by 2017 ESC guidelines 
   
WILL-BLEED score 0.592 (0.494-0.690) 0.624 (0.564-0.684) 0.707 (0.651-0.763) 
CRUSADE score 0.561 (0.470-0.652) 0.583 (0.525-0.641) 0.640 (0.582-0.699) 
Papworth score 0.486 (0.381-0.591) 0.523 (0.464-0.581) 0.578 (0.521-0.634) 
TRUST score 0.497 (0.399-0.595) 0.554 (0.492-0.615) 0.643 (0.584-0.7019 
TRACK score 0.484 (0.384-0.584) 0.535 (0.469-0.600) 0.617 (0.584-0.701) 
CathPCI score 0.558 (0.460-0.656) 0.611 (0.552-0.670) 0.675 (0.620-0.730) 
    
P2Y12 rec. antagonists paused 
according to the 2017 ESC guidelines 
   
WILL-BLEED score 0.581 (0.531-0.631) 0.593 (0.566-0.621) 0.687 (0.656-0.718) 
CRUSADE score 0.534 (0.487-0.580) 0.546 (0.519-0.574) 0.657 (0.626-0.689) 
Papworth score 0.536 (0.490-0.682) 0.557 (0.531-0.584) 0.573 (0.544-0.603) 
TRUST score 0.539 (0.491-0.587) 0.572 (0.545-0.598) 0.653 (0.622-0.684) 
TRACK score 0.520 (0.472-0.568) 0.556 (0.529-0.583) 0.627 (0.594-0.660) 
CathPCI score 0.582 (0.534-0.630) 0.597 (0.570-0.624) 0.676 (0.645-0.707) 
WILL-BLEED score 0.581 (0.531-0.631) 0.593 (0.566-0.621) 0.687 (0.656-0.718) 
Values are areas under the receiver operating characteristics curve with 95% confidence intervals. 
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Table 4. Outcomes. 
 Participating centers 
Outcomes Overall A B C D E F G H I J K L M N O p-value 
 no. 7118 no. 1045 no. 763 no. 659 no. 613 no. 523 no. 503 no. 494 no. 444 no. 433 no. 415 no. 404 no. 226 no. 224 no. 205 no. 167  
Hospital/30-day mortality 275 (3.9) 23 (2.2) 7 (0.9) 6 (0.9) 10 (1.6) 22 (4.2) 6 (1.2) 21 (4.3) 8 (1.8) 8 (1.8) 3 (0.7) 5 (1.2) 14 (5.2) 1 (0.4) 7 (3.4) 0 <0.0001 
De novo IABP/ECMOa 188 (2.6) 31 (3.0) 9 (1.2) 6 (0.9) 5 (0.8) 17 (3.3) 21 (4.8) 29 (5.9) 12 (2.7) 6 (1.4) 3 (0.8) 19 (5.4) 14 (6.5) 1 (0.5) 9 (4.7) 6 (3.6) <0.0001 
Stroke 84 (1.2) 21 (2.0) 14 (1.8) 5 (0.8) 5 (0.8) 4 (0.1) 11 (2.2) 3 (0.7) 6 (1.4) 1 (0) 0 1 (0.2) 5 (2.2) 1 (0.4) 1 (0.5) 2 (1.2) 0.010 
DSWI / mediastinitis 177 (2.5) 26 (2.5) 17 (2.2) 30 (4.6) 14 (2.3) 5 (1.0) 16 (3.2) 10 (2.0) 4 (0.9) 13 (3.0) 7 (1.7) 14 (3.5) 13 (5.8) 3 (1.3) 4 (2.0) 1 (0.6) <0.0001 
Acute kidney injury, stage 3a 181 (2.5) 44 (4.3) 15 (2.0) 7 (1.1) 22 (3.6) 16 (3.1) 5 (1.0) 12 (2.5) 7 (1.7) 9 (2.1) 6 (1.5) 13 (3.3) 12 (5.4) 2 (0.9) 6 (3.0) 5 (3.0) <0.0001 
                  
Bleeding-related outcomes                  
Nadir hematocrit, op. day 30±5 29±4 30±4 34±4 31±5 29±4 33±3 29±5 31±5 30±4 28±4 26±4 28±5 26±4 30±3 28±4 <0.0001 
Drainage output, 12 h (mL) 464±311 505±332 360±172 585±268 493±230 339±141 385±301 554±296 327±193 644±490 317±136 751±502 368±222 288±91 373±211 526±247 <0.0001 
RBC transfusion, 
intraoperatively 
1180 (16.6) 178 (17.0) 96 (12.6) 67 (10.2) 39 (6.4) 30 (5.7) 124 (24.8) 38 (7.7) 95 (21.4) 149 (34.4) 76 (18.3) 131 (32.4) 29 (12.8) 39 (17.4) 63 (30.7) 26 (15.6) <0.0001 
RBC units, intraoperatively 0.2±0.4 0.4±1.1 0.2±0.7 0.2±0.7 1±0.6 0.1±0.4 0.5±0.9 0.1±0.6 0.4±0.9 0.8±01.7 0.3±0.7 0.5±0.7 0.2±0.5 0.3±0.6 0.6±1.0 0.3±0.9 <0.0001 
RBC transfusion, overall 2908 (40.9) 397 (38.0) 236 (31.0) 159 (24.1) 160 (26.1) 179 (34.2) 323 (64.5) 239 (48.4) 172 (38.7) 241 (55.7) 151 (36.4) 288 (71.3) 118 (52.2) 67 (29.9) 113 (55.1) 65 (38.9) <0.0001 
RBC units, overall 1.2±2.5 1.3±2.7 0.8±1.5 0.6±1.4 1.1±3.3 0.8±1.9 2.3±3.3 1.1±1.7 1.1±2.0 2.3±3.7 1.0±3.3 1.3±1.1 1.1±1.0 0.6±1.0 1.6±2.5 1.0±1.4 <0.0001 
Fresh frozen plasma  443 (6.2) 40 (3.8) 43 (5.6) 40 (6.1) 33 (5.4) 17 (3.3) 80 (16.0) 2 (0.4) 21 (4.7) 102 (23.6) 8 (1.9) 16 (4.0) 26 (11.5) 1 (0.4) 9 (4.4) 5 (3.0) <0.0001 
Platelets transfusion 544 (7.6) 34 (3.3) 39 (5.1) 30 (4.6) 66 (10.8) 138 (26.4) 29 (5.8) 3 (0.8) 15 (3.4) 138 (31.9) 5 (1.2) 24 (5.9) 7 (3.1) 2 (0.9) 5 (2.4) 9 (5.4) <0.0001 
rFVIIa 11 (0.2) 3 (0.3) 0 0 0 0 1 (0.2) 0 1 (0.2) 0 2 (0.5) 0 0 1 (0.4) 0 3 (1.8) <0.0001 
Cryoprecipitate 18 (0.3) 12 (1.1) 1 (0.1) 0 1 (0.2) 0 0 3 (0.6) 0 0 1 (0.2) 0 0 0 0 0 <0.0001 
Fibrinogen 258 (3.6) 98 (9.4) 25 (3.3) 31 (4.7) 13 (2.1) 0 20 (4.0) 18 (3.6) 0 3 (0.7) 13 (3.2) 0 0 35 (15.6) 0 2 (1.2) <0.0001 
PCC 119 (1.7) 34 (3.3) 4 (0.5) 0 0 0 3 (0.6) 15 (3.0) 0 1 (0.2) 14 (3.4) 0 31 (13.7) 16 (7.1) 1 (0.5) 0 <0.0001 
Resternotomy for bleeding 186 (2.6) 34 (3.3) 16 (2.1) 16 (2.4) 16 (2.6) 9 (1.7) 10 (2.0) 8 (1.6) 4 (0.9) 30 (6.9) 12 (2.9) 13 (3.2) 9 (4.0) 0 2 (1.0) 7 (4.2) <0.0001 
Surgical bleedingc 89 (48.6) 18 (56.2) 9 (56.3) 8 (50.0) 9 (56.3) 6 (66.7) 5 (50.0) 1 (12.5) 0 21 (72.4) 0 7 (53.8) 5 (55.6) 0 0 0 <0.0001 
Diffuse bleedingc 74 (40.4) 12 (36.4) 6 (37.5) 8 (50.0) 3 (18.8) 3 (33.3) 5 (50.0) 7 (87.5) 2 (50.0) 6 (20.7) 11 (91.7) 2 (15.4) 3 (33.3) 0 2 (100) 4 (57.1) <0.0001 
Surgical and diffuse bleedingc 20 (10.8) 2 (6.1) 1 (6.3) 0 4 (25.0) 0 0 0 2 (50.0) 2 (6.9) 1 (8.3) 4 (30.8) 1 (11.1) 0 0 3 (42.9) <0.0001 
Resternotomy > 12 hours 45 (24.3) 6 (18.2) 5 (31.3) 0 4 (25.0) 4 (44.4) 1 (10.0) 7 (87.5) 0 12 (40.0) 4 (33.3) 0 2 (22.2) - 0 0 <0.0001 
UDPB bleeding grades 3-4 601 (8.4) 105 (10.2) 35 (4.6) 56 (8.5) 49 (8.0) 19 (3.7) 53 (10.6) 45 (9.2) 17 (3.8) 82 (20.0) 19 (4.6) 90 (22.3) 13 (5.8) 1 (0.4) 8 (3.9) 9 (5.4) <0.0001 
E-CABG bleeding grades 2-3 463 (6.5) 80 (7.7) 34 (4.5) 34 (5.2) 43 (7.0) 18 (3.4) 59 (11.8) 26 (5.3) 22 (5.0) 76 (16.4) 19 (4.6) 16 (4.0) 13 (5.8) 1 (0.4) 15 (7.3) 7 (4.2) <0.0001 
Continuous variables are reported as the mean ± standard deviation. Categorical variables are reported as counts and percentages. a: excluding patients with preoperative IABP; b: excluding 
patients with preoperative chronic kidney disease class V; c: proportion of among patients who underwent resternotomy for bleeding excluding three patients without data on the source of 
bleeding; IABP: intra-aortic balloon pump; ECMO: extra-corporeal membrane oxygenation; DSWI: deep sternal wound infection; KDIGO: Kidney Disease: Improving Global Outcomes; RBC: red 
blood cell; PCC: prothrombin complex concentrate. 
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Table 5. Surgical sources of bleeding detected at resternotomy in 109 patients. 
Sources of bleeding No. (%) 
Coronary anastomosis 25 (20.5) 
Int. mammary a. branch 24 (19.7)  
Int. mammary a.  harvesting site 22 (18.0) 
Sternum 16 (13.1) 
Vein graft branch 13 (10.7) 
Neck, mediastinal and pericardial vessels 8 (6.6) 
Pace-maker wire insertion site 3 (2.5) 
Ventricular wall or epicardium 3 (2.5) 
Atrial cannulation site 3 (2.5) 
Aortic cannulation site 2 (1.6) 
Ascending aorta 1 (0.8) 
Coronary anastomosis after pacemaker wire removal 1 (0.8) 
Radial a. graft branch 1 (0.8) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend to figures 
Figure 1. Prevalence of patients with P2Y12 inhibitors pause shorter than five days as well as shorter than the period suggested by the 2017 ESC guidelines, 
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i.e. ticagrelor <3 days, clopidogrel <5 days and prasugrel <7 days before coronary artery bypass grafting in the participating centers (inter-istitutional 
difference, p<0.0001 for all P2Y12 inhibitors). 
Figure 2. Risk-adjusted rates with 95% confidence intervals of resternotomy for bleeding and surgical site bleeding in participating centers. Red lines are the 
rates in the overall series, red dots indicate centers with significantly higher and blue dots indicate centers with significantly lower risk-adjusted rates. 
Figure 3. Risk-adjusted rates with 95% confidence intervals of red blood cell (RBC) transfusion as well as severe-massive bleeding according to the Universal 
Definition of Perioperative Bleeding (UDPB) and E-CABG bleeding severity criteria in the participating centers. Red lines are the rates in the overall series, red 
dots indicate centers with significantly higher and blue dots indicate centers with significantly lower risk-adjusted rates. 
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